Quanterix offers Simoa technology, utilizing microarray printer and ultrasensitive immunoassay platforms based on bead and planar technologies, to enable ultra-sensitive biomarker detection for earlier disease diagnosis and precise treatment methods in various therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious disease.